TKT then inhibits the expression of the farnesoid receptor (FXR) (a tumor suppressor gene) by promoting the binding of histone deacetylase-3 (HDAC-3) to the FXR promoter, causing increases in intrahepatic bile acid (related to the occurrence of liver cancer). The gene discussed is HDAC3; the disease is liver cancer.